| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003246 |
| Receipt No. | R000003928 |
| Scientific Title | Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study |
| Date of disclosure of the study information | 2010/03/01 |
| Last modified on | 2019/09/01 (Ver. 7) |
| Basic information | ||
| Public title | Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study | |
| Acronym | Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study | |
| Scientific Title | Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study | |
| Scientific Title:Acronym | Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study | |
| Region |
|
|
| Condition | ||
| Condition | gynecological cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | confirmation of safety of enoxaparin sodium after oncogynecological surgical patients |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | incidence of bleeding event |
| Key secondary outcomes | incidence of venous thromboembolism |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Prevention | ||
| Type of intervention |
|
||
| Interventions/Control_1 | low weight molecular heparin 2times per day 7-14 days | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | oncogynecological surgical patients | |||
| Key exclusion criteria | bleeder etc | |||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | shizuoka cancer center | ||||||
| Division name | gynecology | ||||||
| Zip code | 4118777 | ||||||
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka | ||||||
| TEL | 055-989-5222 | ||||||
| n.takahashi@scchr.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | shizuoka cancer center | ||||||
| Division name | gynecology | ||||||
| Zip code | 4118777 | ||||||
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka | ||||||
| TEL | 055-989-5222 | ||||||
| Homepage URL | |||||||
| n.takahashi@scchr.jp | |||||||
| Sponsor | |
| Institute | Kansai clinical oncology group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kansai clinical oncology group |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB |
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka |
| Tel | 0559895222 |
| irb@scchr.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 大阪医科大学(大阪府)、関西労災病院(兵庫県)、京都府立医科大学(京都府)、静岡がんセンター(静岡県)、聖隷浜松病院(静岡県)、名古屋市立大学(愛知県)、奈良医科大学(奈良県)、奈良県立奈良病院(奈良県)、兵庫医科大学(兵庫県)、三重大学(三重県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000003928 |